Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKesson
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: May 20, 2022

SEGLUROMET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Segluromet, and what generic alternatives are available?

Segluromet is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-four patent family members in forty-eight countries.

The generic ingredient in SEGLUROMET is ertugliflozin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the ertugliflozin; metformin hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Segluromet

Segluromet was eligible for patent challenges on December 19, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 21, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for SEGLUROMET
International Patents:84
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for SEGLUROMET
What excipients (inactive ingredients) are in SEGLUROMET?SEGLUROMET excipients list
DailyMed Link:SEGLUROMET at DailyMed
Drug patent expirations by year for SEGLUROMET
Drug Prices for SEGLUROMET

See drug prices for SEGLUROMET

DrugPatentWatch® Estimated Generic Entry Opportunity Date for SEGLUROMET
Generic Entry Date for SEGLUROMET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for SEGLUROMET
Drug ClassBiguanide

US Patents and Regulatory Information for SEGLUROMET

SEGLUROMET is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEGLUROMET is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SEGLUROMET

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

FDA Regulatory Exclusivity protecting SEGLUROMET

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

International Patents for SEGLUROMET

When does loss-of-exclusivity occur for SEGLUROMET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 99
Estimated Expiration: See Plans and Pricing

Australia

Patent: 10310956
Estimated Expiration: See Plans and Pricing

Canada

Patent: 77857
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 120289
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0150107
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 15949
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 96583
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 12011946
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 1983
Estimated Expiration: See Plans and Pricing

Patent: 1290267
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 96583
Estimated Expiration: See Plans and Pricing

Japan

Patent: 96156
Estimated Expiration: See Plans and Pricing

Patent: 13509393
Estimated Expiration: See Plans and Pricing

Montenegro

Patent: 016
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 9945
Estimated Expiration: See Plans and Pricing

Poland

Patent: 96583
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 96583
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 827
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 96583
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1203486
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1426180
Estimated Expiration: See Plans and Pricing

Patent: 120093321
Estimated Expiration: See Plans and Pricing

Spain

Patent: 27179
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 3416
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SEGLUROMET around the world.

Country Patent Number Title Estimated Expiration
Brazil PI0918841 derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais e composições farmacêuticas See Plans and Pricing
Georgia, Republic of P20135803 DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES See Plans and Pricing
Japan 4825322 See Plans and Pricing
Hong Kong 1193606 二氧雜-雙環 辛烷- -三醇衍生物 (DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES -[321]-234-) See Plans and Pricing
Croatia P20150107 See Plans and Pricing
South Africa 201203486 DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SEGLUROMET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2334687 30/2018 Austria See Plans and Pricing PRODUCT NAME: ERTUGLIFLOZIN, GEGEBENENFALLS ALS KRISTALLFORM, INSBESONDERE ALS CO-KRISTALL MIT L-PYROGLUTAMINSAEURE, UND INSBESONDERE ALS ERTUGLIFLOZIN L-PYROGLUTAMINSAEURE; REGISTRATION NO/DATE: EU/1/18/1267 (MITTEILUNG) 20180323
2334687 2018/028 Ireland See Plans and Pricing PRODUCT NAME: ERTUGLIFLOZIN, OPTIONALLY AS A CRYSTAL FORM, PARTICULARLY AS A CO-CRYSTAL WITH L-PYROGLUTAMIC ACID, AND SPECIFICALLY AS ERTUGLIFLOZIN L-PYROGLUTAMIC ACID; REGISTRATION NO/DATE: EU/1/18/1267/001 EU/1/18/1267/012 20180321
2334687 CA 2018 00025 Denmark See Plans and Pricing PRODUCT NAME: ERTUGLIFLOZIN, EVENTUELT SOM EN KRYSTALFORM, SAERLIGT SOM ET CO-KRYSTAL MED L-PYROGLUTAMINSYRE OG SPECIFIKT SOM ERTUGLIFLOZIN-L-PYROGLUTAMINSYRE; NAT. REG. NO/DATE: EU/1/18/1267/001-012 20180323; FIRST REG. NO/DATE: EU EU/1/18/1267/001/012 20180323
2334687 PA2018510,C2334687 Lithuania See Plans and Pricing PRODUCT NAME: ERTUGLIFLOZINAS, PASIRINKTINAI KAIP KRISTALINE FORMA, YPAC KAIP KO-KRISTALAS SU L-PIROGLUTAMO RUGSTIMI, IR YPAC KAIP ERTUGLIFLOZINO L-PIROGLUTAMO RUGSTIS; REGISTRATION NO/DATE: EU/1/18/1267 20180321
2334687 C02334687/01 Switzerland See Plans and Pricing PRODUCT NAME: ERTUGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 66577 18.10.2018
2334687 1890026-6 Sweden See Plans and Pricing PRODUCT NAME: ERTUGLIFLOZIN,OPTIONALLY IN THE FORM OF ERTUGLIFOZIN L- PYROGLUTAMIC ACID; REG. NO/DATE: EU/1/18/1267 20180323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKinsey
Merck
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.